AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 39265173
Drug: Tamsulosin (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin (0.4 mg)
Trial: 34810364
Drug: Early implant
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early implant placement at 8 weeks with A-PRF
Trial: 34810364
Drug: Early implant
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early implant placement at 6 weeks with A-PRF
Trial: 35304019
Drug: Ginger capsules
DrugBank: Ginger (DB10344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger capsules (250 mg, four capsules)
Trial: 35304019
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules (four capsules)
Trial: 32236602
Drug: Glutathione (ROS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutathione (ROS inhibitor)
Trial: 34127107
Drug: Lurasidone (20-80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone (20-80 mg/d)
Trial: 32334460
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose prednisolone (5 mg daily for two months)
Trial: 33512942
Drug: Protocol-guided strategy
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol-guided strategy utilizing stroke volume variation to guide administration of bolus fluid
Trial: 33160266
Drug: Single-facet G-coefficients
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-facet G-coefficients averaged across laboratories.
Trial: 33517741
Drug: Blind injection
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blind injection
Trial: 35460158
Drug: Intralesional tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intralesional tranexamic acid (TXA) 4 mg/ml
Trial: 33028796
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no surface treatment)
Trial: 32927075
Drug: High-dose digestive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose digestive enzyme treatment (Excelase: 3.0 g/day; Pancreatin: 3.0 g/day; Berizym: 3.0 g/day; Toughmac-E: 3.0 g/day)
Trial: 32927075
Drug: Normal-dose digestive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal-dose digestive enzyme treatment (Excelase: 3.0 g/day)
Trial: 38844941
Drug: Rivaroxaban (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (20 mg or 10 mg)
Trial: 38844941
Drug: Aspirin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (100 mg)
Trial: 35101183
Drug: FeNO plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FeNO plus symptom-guided treatment
Trial: 35101183
Drug: Symptom-guided treatment
RxNorm normalized name: Pamprin Multi-Symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptom-guided treatment alone (standard care)
Trial: 34562328
Drug: 2-L polyethylene
RxNorm normalized name: Iron(2+) L-ascorbate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-L polyethylene glycol with ascorbic acid (PEG-Asc)
Trial: 36220337
Drug: Intensive systolic
RxNorm normalized name: Bystolic
DrugBank: Nebivolol (DB04861)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive systolic blood pressure (SBP) treatment
Trial: 32668428
Drug: Intravenous MEPD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous MEPD injection
Trial: 32668428
Drug: Intratympanic MEPD
RxNorm normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intratympanic MEPD injection
Trial: 36469914
Drug: Dapagliflozin, 10
RxNorm normalized name: Dapagliflozin, 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin, 10 mg once daily
Trial: 33174126
Drug: Antibiotic time-out
RxNorm normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotic time-out protocol
Trial: 33622590
Drug: Multivalent vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivalent vaccine containing nine serogroups (A, B, C, D, E, F, G, H, I)
Trial: 33622590
Drug: Sequential bivalent
RxNorm normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential bivalent vaccines
Trial: 33622590
Drug: Monthly foot-bathing
RxNorm normalized name: Fungi-Nail Toe and Foot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly foot-bathing
Trial: 32279529
Drug: Antihypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatment (Olmesartan), duration 1 year
Trial: 32769524
Drug: Topical Tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical Tranexamic Acid (10%) with microneedling
Trial: 32531798
Drug: CZP 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CZP 200 mg every 2 weeks (Q2W)
Trial: 33953123
Drug: Methadone +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone + disulfiram (250 mg/day)
Trial: 33039992
Drug: Oral corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral corticosteroids (meprednisone or prednisone for 6 months)
Trial: 35659776
Drug: Sleep-Extend intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sleep-Extend intervention (6 weeks of using a Fitbit, weekly digital content, and weekly coaching)
Trial: 35037278
Drug: High-dose topiramate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose topiramate (up to 250 mg/day)
Trial: 35037278
Drug: Low-dose topiramate
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose topiramate (up to 125 mg/day)
Trial: 39013870
Drug: Pembrolizumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (200 mg every 3 weeks)
Trial: 34584971
Drug: 1 L
RxNorm normalized name: BLUE 1 LAKE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 L PEG+Asc
Trial: 32962934
Drug: Continuous remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous remifentanil infusion (R)
Trial: 33337491
Drug: Vida Sana
RxNorm normalized name: Vidaza
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Vida Sana intervention (culturally adapted lifestyle intervention with family-based orientation and 22 group sessions over 12 months, plus monthly emails for an additional 12 months)
Trial: 35344089
Drug: Standard position
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard position (300 µm pre- and post-anterior capsule)
Trial: 32907904
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg elobixibat (EXB) monotherapy
Trial: 33739852
Drug: Low-risk patients
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-risk patients compared to standard-risk patients with identical therapy
Trial: 32921069
Drug: Aggressive metastasis-directed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive metastasis-directed therapy (MDT) with surgery and/or hypofractionated image-guided radiation therapy (HIGRT)
Trial: 32921069
Drug: Improved systemic
RxNorm normalized name: Improvest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Improved systemic therapies (targeted agents and immunotherapy)
Trial: 35296289
Drug: Information related
RxNorm normalized name: INFORMATION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Information related to AstraZeneca's vaccine safety
Trial: 35234092
Drug: 2DR (bDRV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2DR (bDRV 800 mg + dolutegravir 50 mg)
Trial: 32299093
Drug: MDS‐associated mutations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDS‐associated mutations after high-dose therapy
Trial: 32801257
Drug: Split-dose (SPD)
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split-dose (SPD) 2 L polyethylene glycol electrolyte solution, 1 L PEG between 8-9 pm the day before and 1 L PEG between 5-6 am on the day of colonoscopy.
Trial: 32801257
Drug: Split-dose (SPD)
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split-dose (SPD) group
Trial: 32801257
Drug: Single-dose (SID)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose (SID) group
Trial: 34481095
Drug: 6-Hz tACS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-Hz tACS for 26.67 min daily for three days (Long Exposure Theta group)
Trial: 34481095
Drug: 6-Hz tACS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-Hz tACS for 5.33 min daily (Short Exposure Theta group)
Trial: 39697620
Drug: Abemaciclib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abemaciclib plus endocrine therapy (ET)
Trial: 39463748
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine therapy (ET) alone
Trial: 34398667
Drug: Chloroquine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine (25 mg base/kg of body weight) plus primaquine (0.5 mg base/kg/day for 14 days)
Trial: 34398667
Drug: Dihydroartemisinin-piperaquine (dihydroartemisinin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroartemisinin-piperaquine (dihydroartemisinin at 7 mg/kg and piperaquine at 55 mg/kg) plus primaquine (0.5 mg base/kg/day for 14 days)
Trial: 34398667
Drug: Dihydroartemisinin-piperaquine (dihydroartemisinin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroartemisinin-piperaquine (dihydroartemisinin at 7 mg/kg and piperaquine at 55 mg/kg) plus primaquine (1 mg/kg/day for 7 days)
Trial: 34398667
Drug: Chloroquine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine (25 mg base/kg of body weight) plus primaquine (1 mg/kg/day for 7 days)
Trial: 32166899
Drug: 5 mg/day
RxNorm normalized name: Lyllana 0.05 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/day Linagliptin
Trial: 32711565
Drug: Pidotimod (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pidotimod (2 vials of 400 mg daily) with betamethasone 0.5-1 mg on need
Trial: 32711565
Drug: Betamethasone 0.5-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betamethasone 0.5-1 mg on need
Trial: 35340120
Drug: Oral tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tranexamic acid (TA) 325 mg every 12 hours plus f‐TCC (fluocinolone‐based triple combination cream) every 24 hours
Trial: 35340120
Drug: Oral tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tranexamic acid (TA) 325 mg every 12 hours
Trial: 32243384
Drug: Acupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture combined with conventional drug treatment
Trial: 34353696
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of IL-6 elevation and high serum glucose levels
Trial: 35794044
Drug: Late oral
RxNorm normalized name: Adalate Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late oral feeding
Trial: 34583100
Drug: Cognitive‐Behavioral Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive‐Behavioral Therapy for Seasonal Affective Disorder (CBT‐SAD)
Trial: 34015829
Drug: Yoga therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yoga therapy (Group 2)
Trial: 34015829
Drug: Guideline-directed therapy
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-directed therapy (Group 1)
Trial: 35361630
Drug: Nintedanib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nintedanib plus chemotherapy
Trial: 32857933
Drug: Escitalopram (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (15 mg/d forced titration to 20 mg/d)
Trial: 32943094
Drug: Monitoring adherence
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Monitoring adherence and inhalation technique without feedback
Trial: 33084254
Drug: Mirtazapine (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirtazapine (titrated up to 45 mg/d for 8 weeks)
Trial: 35620951
Drug: Compound lidocaine
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound lidocaine cream with roller microneedles for 10 min, followed by rolling for 20 min (30 min test side)
Trial: 34424217
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea mouthwash (13% infusion prepared with 13 g of green tea in 100 mL saline solution)
Trial: 35531572
Drug: Whitegold Office
RxNorm normalized name: Office First Aid Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whitegold Office 35% (WGO) bleaching agent
Trial: 35531572
Drug: Whiteness HP
RxNorm normalized name: HP 502
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whiteness HP Auto Mixx 35% (WHP) bleaching agent
Trial: 35531572
Drug: Combined bleaching
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined bleaching agents (WGO and WHP)
Trial: 35727580
Drug: Varenicline, 1
RxNorm normalized name: Varenicline, 1 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline, 1 mg, twice daily for 12 weeks
Trial: 32539908
Drug: DBV712 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DBV712 250 µg epicutaneous patch
Trial: 37345996
Drug: Combination intervention
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination intervention
Trial: 33288333
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy rehabilitation program combined with music therapy
Trial: 33288333
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy rehabilitation program without music therapy
Trial: 35792365
Drug: Metformin 850
RxNorm normalized name: metFORMIN 850 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 850 mg
Trial: 35344737
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (1.9 g docosahexaenoic acid and 0.22 g eicosapentaenoic acid)
Trial: 32544011
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg CoQ10 capsules per day
Trial: 32955672
Drug: Standard LRYGB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard LRYGB (S‐LRYGB) (RL 150 cm, BPL 60 cm, and variable CC length)
Trial: 36184601
Drug: L-BAIBA 1500
RxNorm normalized name: L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-BAIBA 1500 mg (B1500)
Trial: 36184601
Drug: L-BAIBA 500
RxNorm normalized name: arginine
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: L-BAIBA 500 mg (B500)
Trial: 36184601
Drug: L-BAIBA 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-BAIBA 250 mg (B250)
Trial: 36184601
Drug: Valine 1500
RxNorm normalized name: Valine
DrugBank: Valine (DB00161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valine 1500 mg (V1500)
Trial: 33455201
Drug: Non-fluorescent ELP
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-fluorescent ELP fusion proteins co-transfected with a fluorescent ELP marker; specific dosage and duration not mentioned.
Trial: 33455201
Drug: Single transfected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single transfected treatments of ELP fusions; specific dosage and duration not mentioned.
Trial: 33196146
Drug: 4.0-mm annular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.0-mm annular treatment zone
Trial: 32100502
Drug: Acupoint catgut
RxNorm normalized name: CATGUT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint catgut embedding therapy combined with rehabilitation training
Trial: 34921121
Drug: Treatment arm
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment arm (specific treatment not detailed)
Trial: 39264623
Drug: Alteplase (0.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alteplase (0.9 mg/kg)
Trial: 33223426
Drug: 7 mg
RxNorm normalized name: pectin 7 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 mg GSK958108
Trial: 34048940
Drug: Escitalopram 20
RxNorm normalized name: escitalopram 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram 20 mg/day
Trial: 33865691
Drug: Enhanced treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced treatment as usual arm, n = 335
Trial: 32877576
Drug: rSARS-CoV-2 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rSARS-CoV-2 vaccine with Matrix-M1 adjuvant
Trial: 32877576
Drug: rSARS-CoV-2 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rSARS-CoV-2 vaccine without Matrix-M1 adjuvant
Trial: 34936382
Drug: Doxycycline 20
RxNorm normalized name: doxycycline 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 20 mg
Trial: 35403213
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of fresh cow's milk (ED05)
Trial: 32110882
Drug: Ketamine (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.15 mg/kg (LBM))
Trial: 32471492
Drug: Administration of
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of Patient Health Questionnaire (PHQ‐9) as a PROM within 2 weeks of diagnosis and at follow‐up 4 weeks later. General practitioners trained in interpreting scores and providing feedback.
Trial: 35909461
Drug: Trusopt® eye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trusopt® eye drops solution
Trial: 39591972
Drug: Immune checkpoint
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune checkpoint inhibitors (ICIs)
Trial: 33387930
Drug: EMS treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMS treatments
Trial: 33387930
Drug: Comparison with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison with published treatment time data from other EMS systems
Trial: 33245708
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy (listening to music once a day)
Trial: 35469036
Drug: LIFT +
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LIFT + BM-MNC injection
Trial: 32251757
Drug: Concurrent chemoradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiation therapy
Trial: 36123681
Drug: Complete vaccination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complete vaccination with Gam-COVID-Vac (14 days or more after the second dose)
Trial: 38647051
Drug: Investigator-assigned therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigator-assigned therapy (IAT; valganciclovir/ganciclovir, foscarnet, or cidofovir)
Trial: 35809742
Drug: Ropivacaine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine infusion via TAP catheter
Trial: 32825845
Drug: Low-intensity intervention
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity intervention (standard treatment, guideline-based municipal smoking cessation program)
Trial: 33884980
Drug: Intranasal dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal dexmedetomidine 2 μg/kg
Trial: 34498946
Drug: rHuEPO (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHuEPO (400 IU/kg body wt) injection
Trial: 35281985
Drug: Intraparenchymal injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraparenchymal injection of placenta MSC-derived Exosome
Trial: 34894771
Drug: Control (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (oral diazepam 5 mg and i.m. injection of pethidine)
Trial: 34894771
Drug: Combined (acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined (acupuncture + control drugs)
Trial: 39615889
Drug: Placebo (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline solution)
Trial: 33293212
Drug: Icenticaftor 450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Icenticaftor 450 mg bid for 14 days
Trial: 38810093
Drug: Pravastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (40 mg)
Trial: 33624584
Drug: New favipiravir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New favipiravir tablet formulation
Trial: 33624584
Drug: Reference favipiravir
RxNorm normalized name: favipiravir
DrugBank: Favipiravir (DB12466)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Reference favipiravir tablet formulation
Trial: 34548165
Drug: 1,000 mg
RxNorm normalized name: bran 1,000 mg ORAL WAFER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 mg PO acetaminophen (group B)